Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Capecitabine Maintenance After CRT for ESCC
NCT07177794Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2025
- Primary completion
- May 2028
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Toripalimab + Capecitabine with Observation (2 arms). Primary endpoint: Progression-Free Survival up to 36 months. Started Sep 2025; status: recruiting.
02
Drugs
toripalimabcapecitabine
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07177794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177794.